SEC Form 4 · accession 0001127602-17-004209
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Norbert W Bischofberger
Officer — EVP, R&D and CSO
Period of report
Feb 2, 2017
Accepted (ET)
Feb 6, 2017 · 9:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F1 | $72.25 | Feb 2, 2017 | A | 104,570 | A | — | Feb 2, 2027 | Common Stock | 104,570 | 104,570 | D |
Explanation of responses
- F1The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.